Using AI-Powered Heart Monitors to Predict and Prevent AFib with Mark Goddard Infobionic.AI
Release Date: 09/03/2025
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion TRANSCRIPT
Empowered Patient Podcast
Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting. Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...
info_outline
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion
Empowered Patient Podcast
Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting. Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...
info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech TRANSCRIPT
Empowered Patient Podcast
Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...
info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech
Empowered Patient Podcast
Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...
info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT
Empowered Patient Podcast
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...
info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx
Empowered Patient Podcast
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...
info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics TRANSCRIPT
Empowered Patient Podcast
Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds. Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...
info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics
Empowered Patient Podcast
Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds. Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...
info_outline
Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals TRANSCRIPT
Empowered Patient Podcast
Paul Howe, COO of Protega Pharmaceuticals, is focused on how abuse-deterrent technology can address the opioid crisis and the need for mandates for insurance coverage of safer abuse-deterrent formulations. The SentryBond technology was specifically designed for immediate-release opioids to make it difficult to manipulate pills for abuse via crushing, inhaling, or injecting. Protega partnered with software company Opus to offer a program that helps educate chronic pain patients, manage their treatment, and provides physicians with risk stratification data to improve care and reduce the...
info_outline
Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals
Empowered Patient Podcast
Paul Howe, COO of Protega Pharmaceuticals, is focused on how abuse-deterrent technology can address the opioid crisis and the need for mandates for insurance coverage of safer abuse-deterrent formulations. The SentryBond technology was specifically designed for immediate-release opioids to make it difficult to manipulate pills for abuse via crushing, inhaling, or injecting. Protega partnered with software company Opus to offer a program that helps educate chronic pain patients, manage their treatment, and provides physicians with risk stratification data to improve care and reduce the...
info_outlineMark Goddard, Vice President of Clinical Services at Infobionic.AI, describes the remote cardiac monitoring system that provides near real-time monitoring of patients with potential cardiac irregularities. The benefit of continuous monitoring allows for early detection of arrhythmias like atrial fibrillation, a growing concern driven by an aging population and factors like obesity and high blood pressure. AI-driven algorithms are used to analyze ECG data and identify potential issues, enabling proactive treatment and prevention of complications like stroke.
Mark explains, "The focus of our monitoring system is to provide near real-time monitoring of patients who are reporting maybe cardiac irregularities. The whole idea is to provide that near-real-time access to cardiac information so that arrhythmias can be identified relatively quickly. Additionally, the treatments for those arrhythmias are relatively quick as well, providing better patient outcomes. Just related to the fact that the data is always there, and it comes in maybe a minute or two behind live."
"We are partnered with a major health system that has an AI engine that is basically developing AI tools that can be utilized in cardiac monitors. And just looking at the patient's ECG, they're able to determine the potential for arrhythmias that may not have occurred yet. And that's kind of what we're focusing on. The ability to review ECG and understand those little nuances that may indicate, hey, this patient's going to have an event like atrial fibrillation, which is the most common irregular rhythm there is, especially for an aging population. Identifying those folks early can really help with not only the outcome for the patient, in that they're not going to run into the problems you may have if you don't recognize you have atrial fibrillation, but it'll also decrease healthcare costs, which in the end helps everybody."
#InfobionicAI #MedAI #Cardiology #AFib #HeartMonitor #CardiacTracking
